PTGX Stock: Price, Earnings History and SEC Filings
Protagonist Therapeutics, Inc. (PTGX) last traded at $144.85, up 0.35% on the latest session and up 2.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $2.29 against an analyst estimate of $2.11, a beat of 8.5%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
PTGX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $2.29 | $2.11 | +8.53% |
| Mar 2026 | May 5, 2026 | $0.05 | $-0.65 | +107.69% |
| Dec 2025 | Feb 25, 2026 | $-0.69 | $-0.53 | -30.19% |
| Sep 2025 | Nov 6, 2025 | $-0.62 | $-0.59 | -5.08% |
PTGX beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How PTGX reacts to earnings
Across its last 8 earnings releases, PTGX moved 3.1% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | After close | +6.45% |
| 2026-05-05 | After close | +4.80% |
| 2026-02-25 | After close | +1.48% |
| 2025-11-06 | After close | -0.30% |
| 2025-08-06 | After close | -5.39% |
| 2025-05-06 | After close | +2.57% |
| 2025-02-21 | Before open | +0.68% |
| 2024-11-07 | After close | -2.90% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
PTGX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $46M | -$130M | $56M | -282.8% | $-2.05 |
| 2024 | $434M | $275M | $183M | 63.3% | $4.23 |
| 2023 | $60M | -$79M | -$71M | -131.6% | $-1.39 |
| 2022 | $27M | -$127M | -$109M | -479.3% | $-2.60 |
| 2021 | $27M | -$126M | -$109M | -458.9% | $-2.71 |
| 2020 | $29M | -$66M | -$73M | -231.1% | $-1.92 |
| 2019 | $231000 | -$77M | -$42M | -33414.3% | – |
| 2018 | $31M | -$39M | -$50M | -125.9% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for PTGX
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 18, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 10-Q · May 5, 2026
- 8-K · May 5, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 28, 2026
- 10-K · Feb 25, 2026
- 8-K · Feb 25, 2026Results of operations, Financial statements and exhibits
- 8-K · Jan 12, 2026Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Nov 6, 2025
Insider filing activity
PTGX insiders filed 4 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
PTGX news
- Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings GrowthOct 29, 2026 · finance.yahoo.com
- Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?Oct 28, 2026 · finance.yahoo.com
- Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026Oct 27, 2026 · finance.yahoo.com
- J&J Stock Reclaims 50-Day SMA: Is it Time to Buy, Sell or Hold?Oct 23, 2026 · finance.yahoo.com
- A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on MondayOct 20, 2026 · finance.yahoo.com
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. (PTGX) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.